Table 2.
A total of twelve patients on either infliximab or adalimumab were included in the case serie
| Patient | Age (yr) | Sex | Diagnosis | Montreal classification | Duration of disease (yr) | Previous anti-TNF therapy? | Immunomodulator therapy? |
| 1 | 24 | M | CD | A2L3B1 | 5 | Y | Previous - MTX |
| 2 | 46 | M | UC | E3 | 10 | N | Previous - 6MP |
| 3 | 71 | M | CD | A3L1B2 | 4 | N | Previous - 6MP |
| 4 | 31 | F | CD | A2L1B2 | 9 | Y | Current - 6MP |
| 5 | 46 | F | CD | A2L3B2p | 5 | N | None |
| 6 | 41 | M | UC | E2 | 18 | N | Current - AZA |
| 7 | 53 | F | UC | E2 | 24 | Y | Previous - MTX |
| 8 | 21 | M | UC | E3 | 1 | N | Current - MTX |
| 9 | 67 | M | CD | A3L2B1 | 3 | N | None |
| 10 | 26 | M | CD | A1L2B1 | 11 | N | None |
| 11 | 49 | F | CD | A2L3B2 | 30 | N | None |
| 12 | 25 | M | CD | A2L1B2 | 7 | Y | Current - MTX |
Montreal classification CD: Age at Diagnosis (A1: Less than 16 years; A2: Between 17 and 40 years; A3: Over 40 years). Location (L1: Ileal; L2: Colonic; L3: Ileocolonic; L4: Isolated upper digestive tract). Behavior (B1: Non-stricturing, non-penetrating; B2: Structuring; B3: Penetrating; p: Perianal). Montreal classification UC: Location (E1: Proctitis; E2: Left-sided; E3: Extensive or pancolitis). M: Male; F: Female; CD: Crohn’s disease; UC: Ulcerative colitis; MTX: Methotrexate; 6-MP: 6-mercaptopurine; AZA: Azathioprine; TNF: Tumor necrosis factor.